Longfellow Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Longfellow Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$1.69K	–	267
2025 Q3	$1.69K	Hold	3	–	–	﹤0.01%	223
2025 Q2	$1.57K	Hold	3	–	–	﹤0.01%	234
2025 Q1	$1.9K	Hold	3	–	–	﹤0.01%	226
2024 Q4	$2.14K	Hold	3	–	–	﹤0.01%	228
2024 Q3	$3.15K	Hold	3	–	–	﹤0.01%	205
2024 Q2	$3.15K	Buy	3 +1	+50%	+$969	﹤0.01%	196
2024 Q1	$1.93K	Hold	2	–	–	﹤0.01%	229
2023 Q4	$1.76K	Hold	2	–	–	﹤0.01%	207
2023 Q3	$1.65K	Hold	2	–	–	﹤0.01%	196
2023 Q2	$1.44K	Hold	2	–	–	﹤0.01%	231
2023 Q1	$1.64K	Hold	2	–	–	﹤0.01%	225
2022 Q4	$1.44K	Hold	2	–	–	﹤0.01%	236
2022 Q3	$1K	Hold	2	–	–	﹤0.01%	318
2022 Q2	$2K	Buy	2 +1	+100%	+$650	﹤0.01%	300
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	381
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	383
2021 Q3	$1K	Hold	1	–	–	﹤0.01%	413
2021 Q2	$1K	Buy	+1	New	+$507	﹤0.01%	431

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Longfellow Investment Management's REGN Position: Q4 2025 in Review

Longfellow Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 3 shares — an estimated $1.69K sold.

Longfellow Investment Management first reported a position in REGN in Q2 2021 and held it in 18 quarters. The position peaked at $3.15K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Longfellow Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Longfellow Investment Management sold 3 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.69K.
Longfellow Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 18 quarters.
Longfellow Investment Management's Regeneron Pharmaceuticals position peaked at $3.15K in Q3 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Longfellow Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.